Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697839 · ClinicalTrials.gov registry record
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
A clinical trial of Multiple Myeloma and Peripheral Neuropathy, sponsored by Oncotherapeutics.
- Completed
- Registry status
- 110
- Enrollment target
- 3
- Study locations
NCT01697839 is a study of Multiple Myeloma and Peripheral Neuropathy that has completed, run by Oncotherapeutics. The registered enrollment target is 110 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01697839, a study of Multiple Myeloma and Peripheral Neuropathy, has completed, sponsored by Oncotherapeutics.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective study investigating the relationship between vitamin D and peripheral neuropathy (PN) among multiple myeloma (MM) patients treated with either bortezomib or thalidomide. The study consists of a screening period of up to 14 days, followed by a single assessment visit to evaluate vitamin D levels, incidence and severity of PN, neuropathic pain, and markers of depression. Patient charts will also be utilized to assess the frequency of skeletal-related events.
Conditions Studied
Study Locations (3)
California
- Beaver Medical Group - Highland
- James R. Berenson M.D., Inc. - West Hollywood
Illinois
- Illinois Cancer Specialists - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01697839
The ClinicalTrials.gov registry entry for NCT01697839 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (80% lower). The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT01697839 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01697839 about?
NCT01697839 is a clinical study titled "Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients". This is a prospective study investigating the relationship between vitamin D and peripheral neuropathy (PN) among multiple myeloma (MM) patients treated with either bortezomib or thalidomide. The study consists of a screening period of up to 14 days, followed by a single assessment visit to evaluate...
What is the current status of trial NCT01697839?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2012-06. Estimated completion is 2015-08.
What conditions does trial NCT01697839 study?
This clinical trial studies the following conditions: Multiple Myeloma, Peripheral Neuropathy.
Who is sponsoring clinical trial NCT01697839?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01697839 being conducted?
This trial has 3 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.